Results 31 to 40 of about 2,251,685 (405)

International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. [PDF]

open access: yes, 2005
Lung cancer rates have peaked among men in many areas of the world, but rates among women continue to rise. Most lung cancers are squamous cell carcinoma, small cell carcinoma, or adenocarcinoma; trends vary according to type.
Bray, Freddie   +3 more
core   +1 more source

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma [PDF]

open access: yes, 2018
Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient ...
Carnero Moya, Amancio   +5 more
core   +1 more source

Pan-cancer classifications of tumor histological images using deep learning [PDF]

open access: yes, 2020
Histopathological images are essential for the diagnosis of cancer type and selection of optimal treatment. However, the current clinical process of manual inspection of images is time consuming and prone to intra- and inter-observer variability. Here we
Caruana, Dennis   +8 more
core   +1 more source

PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma

open access: yesCell Death and Differentiation, 2021
The prerequisite function of vimentin for the epithelial–mesenchymal transition (EMT) is not clearly elucidated yet. Here, we show that vimentin phosphorylated by PLK1, triggers TGF-β-signaling, which consequently leads to metastasis and PD-L1 expression
Hay-Ran Jang   +6 more
semanticscholar   +1 more source

Cardiac Tamponade Secondary to Metastasis from Adenocarcinoma of the Parotid Gland [PDF]

open access: yes, 2003
BACKGROUND: Metastatic involvement of pericardium producing cardiac tamponade is rare. When occurs it is mainly from the lung, breast and the neoplasms of the lymphoreticular system.
Barbetakis, Nikolaos G   +5 more
core   +4 more sources

MEK5 promotes lung adenocarcinoma [PDF]

open access: yesEuropean Respiratory Journal, 2018
MEK5 acts as an oncogenic driver in mice lung cancer and is pivotal for human lung adenocarcinoma http://ow.ly ...
S?nchez Fern?ndez, Adri?n   +9 more
openaire   +3 more sources

GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma

open access: yesBMC Cancer, 2018
Background Lung adenocarcinoma is the most common type of lung cancer and one of the most lethal and prevalent cancers. Aberrant glycosylation was common and essential in tumorigenesis, with fucosylation as one of the most common types disrupted in ...
Xing Wei   +6 more
doaj   +1 more source

PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity

open access: yesGenome Biology, 2021
Background Although using a blockade of programmed death-ligand 1 (PD-L1) to enhance T cell immune responses shows great promise in tumor immunotherapy, the immune-checkpoint inhibition strategy is limited for patients with solid tumors.
Shuang Qu   +16 more
semanticscholar   +1 more source

EGFR Mutation Status in Uighur Lung Adenocarcinoma Patients

open access: yesChinese Journal of Lung Cancer, 2013
Background and objective Epidermal growth factor receptor (EGFR), a transmembrane protein, is a member of the tyrosine kinase family. Gefitinib, an EGFR tyrosine-kinase inhibitors, has shown a high response rate in the treatment of lung cancer in ...
Li SHAN   +4 more
doaj   +1 more source

Effects of lncRNA PKD2-2-3 on cell proliferation, clone formation, migration, and invasion of lung adenocarcinoma [PDF]

open access: yesZhongguo aizheng zazhi, 2023
Background and purpose: Long non-coding RNA (lncRNA) is abnormally expressed in lung adenocarcinoma patients, and closely related to tumor occurrence, development and chemotherapy resistance.
JIA Liqing, GE Xiaolu, JIANG Lin, ZHOU Xiaoyan
doaj   +1 more source

Home - About - Disclaimer - Privacy